As we look forward to the holiday season, we are filled with gratitude to all our incredible partners. Read More

PlatformQ Health, the National Organization for Rare Disorders (NORD), the International Fibrodyslpasia Ossificans Progressiva Association (IFOPA) Read More

The Asthma and Allergy Foundation of America (AAFA) and PlatformQ Health have extended their long-standing collaboration for another three years to continue bringing trusted digital education to those affected by asthma and related conditions. Read More

As we look forward to the holiday season, we are filled with gratitude to all our incredible partners. Read More

Clinical trials are crucial for advancing care for non-Hodgkin's lymphoma (NHL), however, accrual in these studies remains low. To address this issue, PlatformQ Health, the Leukemia & Lymphoma Society, BlackDoctor.org, and Partners for Advancing Clinical Education co-produced the BUILD-NHL Trial Equity Initiative.  Read More

PlatformQ Health, the Asthma and Allergy Foundation of America (AAFA), and BlackDoctor.org were seeking to understand whether aligned (sequential patient/provider) education could help improve health equity for those suffering from conditions such as asthma and atopic dermatitis. Read More

Clinical trial recruitment has been a persistent problem, with studies showing up to 55% of trials are canceled prematurely due to low enrollment rates. These rates are even more dismal when it comes to diverse populations, including ethnic and racial minorities as well as seniors. Common methods for improving trial access such as transportation supports have been well documented, yet there are numerous other avenues for improving the patient experience that have yet to be uncovered.  Read More

Immunotherapy is increasingly being used to treat patients with melanoma and other types of cancer. Management of these therapies differs distinctly from previous standard-of-care options such as chemotherapy. Optimizing care involves educating a multidisciplinary healthcare team about therapy management as well as educating patients about therapies and the factors that can influence outcomes. Read More

In the wake of FDA approvals for treating myasthenia gravis (gMG, healthcare providers have the ability to individualize treatment. As these new therapies become adopted, it's crucial to educate patients and providers about issues such as disease presentation, comorbidities, and patient preferences that may impact treatment decisions. Read More

The explosion of gene and cell therapies brings promise - and a plethora of questions - from patients and healthcare providers. CAR T-cell therapy is a notable example. These one-time treatments are providing durable remission and in some cases cures of recurrent blood cancers. Due to the complexity of CAR T-cell therapy, it is currently available exclusively at specialized medical centers. Read More

PlatformQ Health is excited to share that our poster session “Incorporating the Patient Voice in Rare Disease Education: Multi Stakeholder Collaborations to Improve Diagnosis, Quality of Care, and Outcomes” was selected to be presented both at the 2023 NORD Breakthrough Summit and at the Lighting Round Poster Presentations taking place from 4:30-5:00 PM on Monday, October 16.  Read More

Numerous posters of educational outcomes have been published at major conferences over the past three years across neuromuscular conditions, including Duchenne muscular dystrophy (DMD), myasthenia gravis (mGM), and spinal muscular atrophy (SMA). These posters highlight the advantages of aligned patient/provider education for closing knowledge gaps and aligning expectations between patients and providers. Read More